Endo International (NASDAQ:ENDP) (TSE:ENL)‘s stock had its “hold” rating restated by equities researchers at Cowen in a research note issued on Friday. They currently have a $9.00 target price on the stock. Cowen’s price objective suggests a potential downside of 33.28% from the stock’s previous close.
Several other brokerages also recently issued reports on ENDP. Mizuho upped their target price on shares of Endo International to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 14th. TheStreet upgraded shares of Endo International from a “d” rating to a “c-” rating in a research note on Monday, August 20th. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Monday, September 24th. Cantor Fitzgerald upped their target price on shares of Endo International from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, October 19th. Finally, Citigroup increased their price objective on shares of Endo International from $11.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.97.
Shares of NASDAQ ENDP traded up $0.30 during midday trading on Friday, hitting $13.49. The stock had a trading volume of 6,440,068 shares, compared to its average volume of 4,723,015. The company has a market cap of $3.59 billion, a PE ratio of 3.51, a P/E/G ratio of 1.54 and a beta of 0.65. Endo International has a 52 week low of $5.27 and a 52 week high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.12. The firm had revenue of $745.00 million for the quarter, compared to the consensus estimate of $694.93 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The business’s revenue was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.91 earnings per share. As a group, equities research analysts forecast that Endo International will post 2.68 earnings per share for the current year.
In related news, Director Roger H. Kimmel sold 26,074 shares of the stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.80% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. United Services Automobile Association increased its holdings in Endo International by 16.7% during the second quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock valued at $391,000 after buying an additional 5,933 shares during the last quarter. Xact Kapitalforvaltning AB increased its holdings in Endo International by 22.2% during the second quarter. Xact Kapitalforvaltning AB now owns 35,715 shares of the company’s stock valued at $337,000 after buying an additional 6,500 shares during the last quarter. James Investment Research Inc. increased its holdings in Endo International by 594.9% during the third quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock valued at $184,000 after buying an additional 9,370 shares during the last quarter. Diamond Hill Capital Management Inc. increased its holdings in Endo International by 1.0% during the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock valued at $10,375,000 after buying an additional 10,600 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Endo International during the third quarter valued at approximately $223,000. 98.43% of the stock is owned by institutional investors and hedge funds.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.